Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 1 Oct - India Ratings reaffirmed Star Health’s AA+ issuer rating and AA subordinate debt rating, both Stable.
Source: Bse
Star Health and Allied Insurance Company Limited (STARHEALTH)
Small CapFinancial Services stocks · Small cap · NSE
Star Health and Allied Insurance Company Limited operates in Health Insurance, within the Financial Services sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 11:45 am ISTDetails
Quote21 Oct, 11:45 am IST
Base fundamentals20 Oct 2026 · screener
Latest result29 Jul, 11:23 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Financial Services P/E 17.0 (n=243)
Technical timing lens
Trend score and candlestick chart
50NeutralSMA20 -3.2% / mo · MACD +
Stock trend: 52
Sector RS: 47
Sector 3M: -5.4% vs Nifty 500 -5.6%
Financial Services FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
STARHEALTHD candles · FIT view+4.5%TODAY · PROVISIONALLatest price ₹540.50 on 2026-10-21
Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
-1.6%
RSI
42
MACD hist
0.25
52W pos
59%
2026-10-21O ₹549.45H ₹549.85L ₹535.65C ₹540.50Vol 66,720 shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
STARHEALTHNifty Financial ServicesNifty 500
- STARHEALTH
- -6.7%
- Nifty 500
- -5.6%
- Nifty Financial Services
- -6.0%
- Vs Nifty 500
- -1.2 pp
Chart stats
19 Oct 2026- From 52W high
- -13.3%
- 52W range position
- 60%
- ATR (14)
- 2.8%
- Volume vs 20D
- 0.06x
- Avg traded value
- ₹53.5 Cr
- 20D price channel
- ₹513 - ₹572.6
₹624.9
₹416.6 - ₹624.9
₹15.1
Latest completed session
20-session average
20.6% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · WATCHLIST32
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent80
Revenue +13.2% · PAT +25.6% YoY
Technical
Neutral50
Price trend and sector-relative-strength timing.
Valuation
Legacy model-47.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence66
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 80/100Rev +13% YoY · PAT +26% YoY · margin expansion · +19% QoQ · operating leverage
Filed 29 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹5,522 Cr | +13.2% | +18.8% |
| EBITDA | ₹749 Cr | +27.4% | +406.1% |
| Operating margin | 14.0% | +200 bps | +1080 bps |
| PAT | ₹550 Cr | +25.6% | +395.5% |
| PAT margin | 10.0% | +98 bps | +757 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 37.80
- P/B
- 4.20
- EV/EBITDA
- 28.33
- Market Cap
- 31906.00Cr
Profitability
- ROE
- 7.61%
- ROCE
- 9.69%
- ROA
- 3.51%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 29.00%
- EPS 5Y
- 20.00%
- Revenue 3Y
- 14.00%
- EPS 3Y
- -3.00%
Balance Sheet
- Debt/Equity
- 0.06
- Interest Coverage
- —
- Altman Z
- 2.63
- Book Value
- 129.00
Cash Flow
- FCF Yield
- 2.53%
- FCF Positive Y
- 5/5
- OCF
- 1873.00 Cr
- EPS TTM
- 14.34
Shareholding
- Promoter Hold
- 58.01%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 60%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 19.1k+7.2% vs prev
Net Profit
₹ CrLatest: 557-13.8% vs prev
Return on Equity
%Latest: 7.3-19.7% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 42.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~3.0% over last month) — short-term momentum negative.
- RSI(14) at 42 — falling, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 14% off 52W high · 30% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
73
RS percentile
Stage 1 Base / Transition
1M return
-0.9%
3M return
-6.7%
6M return
+6.5%
1Y return
+9.6%
RS 1D
0
RS 20D
+1
Sector rank
#9
Industry rank
#17
Stage evidence
- Price is within 0.1% of the 30-week proxy.
- The 30-week proxy changed +2.2% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
neutral
Industry
neutral
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 127.5-0.21%
RS vs Nifty 500128
Valuation & peers
U-Score 32 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 32 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation0/30
Growth14/25
Quality0/20
Balance Sheet7/15
Cash Flow8/10
Piotroski
6/9 (+3)
Penalties
0
Raw sum
32
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
32/100 · legacy band WATCHLIST
Positive drivers
- Cash flow contributes 8/10 to the score.
- Growth contributes 14/25 to the score.
- Balance sheet contributes 7/15 to the score.
Main drags
- Fair-value margin of safety is negative at -47.8%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Insurance valuation: embedded value and VNB quality
Insurance economics depend on long-duration book value and new-business profitability.
Primary lens
P/embedded value where available, plus VNB growth and margin.
Secondary checks
Persistency, product mix, solvency, distribution strength.
Main risk check
Accounting profit is less useful than embedded value quality.
PE
37.8
PB
4.2
EV/EBITDA
28.3
ROE
7.6%
ROCE
9.7%
FCF Yield
2.5%
Debt/Equity
0.1
MoS
-47.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
32
Previous: 32
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-47.8%
Previous: -48.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
32
32
32
32
32
32
32
32
32
32
32
32
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹204.01
-164.9% MoS
Growth-justified P/E
25.5
Growth-justified Value
₹365.67
-47.8% MoS
PEG
1.89
Comparable companies
Peers
Business-comparable peers in Financial Services — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
NIVABUPA
Large
Niva Bupa Health Insurance Company Limited
Insurance
match 152
27
82.2
3.5%
-215%
OVERVALUED
MANAPPURAM
Small
Manappuram Finance Limited
Insurance
match 135
21
21.0
7.0%
-510%
OVERVALUED
GODIGIT
Large
Go Digit General Insurance Limited
Insurance
match 128
36
53.4
12.2%
-111%
WATCHLIST
PILANIINVS
Small
Pilani Investment and Industries Corporation Limited
Insurance
match 127
37
—
0.2%
-40%
WATCHLIST
MFSL
Mid
Max Financial Services Limited
Insurance
match 124
11
407.0
1.5%
-23112%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Star Health and Allied Insurance Company Limited operates in Health Insurance, within the Financial Services sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
66Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 49th percentile of the scored universe and 62nd percentile within Financial Services. Main check: financial discipline is weak at 30/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 21 Oct 2026
management-trust-v1
95 docs text-extracted · 35 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
49th percentile
overall median 67 · Financial Services: 62nd pctile, median 62 · Small: 54th pctile, median 66
Evidence depth
Financial-only
95 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
80
strong · leverage and solvency
Discipline
30
weak · capital discipline
Results
53
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 58%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 2.5%.
- ▸5 years of positive FCF.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸ROE is low at 7.6%.
- ▸ROCE trend is -3.6%.
- ▸Revenue CAGR is 14% but EPS CAGR is -3%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Star Health and Allied Insurance Company Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 22 Sep - Star Health and Allied Insurance Company Limited has informed about the schedule of meet with Analysts/Investors dated September 29, 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 22 Sep - Star Health and Allied Insurance Company Limited has informed about the schedule of meet with Analysts/Investors dated September 28, 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Sep - Star Health to meet JP Morgan India in Mumbai on September 21, 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 Sep - Star Health and Allied Insurance Company Limited has informed about the Schedule of meet with Analyst/Investors dated September 23, 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 Sep - Nomura Asset Management one-on-one investor meeting scheduled in Mumbai on September 22, 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Sep - Star Health schedules one-on-one investor meeting with Franklin Templeton on September 16, 2026 in Chennai.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Sep - Star Health schedules one-on-one virtual meeting with Ellerston Capital on September 16, 2026 in Chennai.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Sep - Star Health schedules one-to-one analyst meetings at Jefferies India Forum on September 18, 2026 in Gurgaon.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Sep - Star Health to host Jefferies India Forum investor meeting on September 18, 2026 in Gurgaon.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Aug - Star Health will hold a one-to-one virtual analyst meeting with Hornbill Capital on August 20, 2026.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 Aug - Star Health and Allied Insurance Company Limited has informed about the Schedule of meet with Analyst/Investor dated August 25, 2026.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.